Professor Michael Belkin Honored with Lifetime Achievement Award at MIXiii 2025

Professor Michael Belkin, Head of NurExone Biologic’s Ophthalmology Project, will receive the Lifetime Achievement Award at MIXiii 2025, Israel’s leading Health Tech conference. This prestigious honor acknowledges Professor Belkin’s pioneering contributions to ophthalmic innovation and medical technology, highlighting his decades-long impact on the field.

A renowned figure in ophthalmology, Professor Belkin is a key scientific advisory board member at NurExone and the inventor of Belkin Vision technology, a groundbreaking glaucoma laser treatment system that was recently acquired by Alcon in a deal valued at up to $466 million.

NurExone Biologic’s Presentation at MIXiii 2025

Alongside this recognition, NurExone Biologic has been selected to present at MIXiii 2025, participating in a special session on Innovation in Ophthalmology. The company will showcase preclinical results demonstrating significant optic nerve regeneration, presenting a promising pathway for treating glaucoma and other neurodegenerative eye diseases.

The presentation, held during the Pharma Company Presentations session, will be moderated by Tarsier Pharma and feature leading biotech companies, including:

       • OptiMedRx

       • Galimedix

       • Ocuvia

       • Everads Therapy

The preclinical study was conducted at Tel Hashomer’s Goldschleger Eye Institute and led by Professor Michael Belkin, Dr. Ifat Sher, and Professor Ygal Rotenstreich.

Advancing Glaucoma Research with ExoPTEN

Building on its neuroprotective research, NurExone is launching a new preclinical study using its lead product, ExoPTEN, in a large-scale animal model. This study aims to replicate and expand upon previously observed positive results, further exploring ExoPTEN’s potential in treating neurodegenerative eye diseases.

Professor Belkin emphasized the significance of this research:

“The potential of ExoPTEN for ophthalmology is truly exciting. Advancing this research could open new doors for treating neurodegenerative eye diseases that are currently untreatable, and I’m thrilled to support NurExone in this groundbreaking work.”

Leadership Perspectives on Professor Belkin’s Impact

Dr. Lior Shaltiel, CEO of NurExone Biologic, expressed the company’s pride in both the advancement of regenerative medicine and Professor Belkin’s well-deserved recognition:

“MIXiii is an incredible platform to showcase NurExone’s groundbreaking work in regenerative medicine and our vision for revolutionizing treatment of certain eye diseases. We are also proud to celebrate Professor Belkin’s extraordinary contributions. His lifelong dedication to medical innovation continues to inspire and drive progress in the field. We are honored to have him as an investor, collaborator, and professional consultant.”

A Legacy of Innovation in Ophthalmology

As NurExone Biologic advances its research in optic nerve regeneration and glaucoma treatment, Professor Michael Belkin’s Lifetime Achievement Award at MIXiii 2025 stands as a testament to his lasting impact on the field of ophthalmology. His visionary contributions continue to drive progress, shaping the future of neuroprotective treatments for vision loss.